Research on Creatine's Potential Role in Treating Depression

A recent wave of scientific inquiry suggests that creatine, a widely used supplement among athletes to enhance muscle growth and performance, may also hold potential as a treatment for depression. Emerging research indicates that creatine could influence brain energy metabolism and neurotransmitter function, pathways linked to mood regulation. A 2020 clinical trial published in *The Journal of Psychiatric Research* found that participants with major depressive disorder who supplemented with creatine alongside antidepressants showed significantly greater symptom improvement compared to those on medication alone. A 2023 review in *Neuroscience & Biobehavioral Reviews* further highlighted creatine’s neuroprotective properties and its role in modulating brain-derived neurotrophic factor (BDNF), a protein associated with neuronal health and resilience to stress.

While these findings are promising, experts caution that the evidence remains preliminary. Most studies to date have been small-scale or short-term, and mechanisms underlying creatine’s antidepressant effects require further exploration. Researchers emphasize the need for larger, long-term trials to confirm efficacy and safety, particularly in diverse populations. Additionally, creatine is not a substitute for established treatments like psychotherapy or prescribed medications, and its use should be discussed with healthcare providers to avoid interactions or misuse.

The potential dual role of creatine in physical and mental health underscores the growing interest in repurposing existing supplements for psychiatric conditions. If validated, such an approach could offer a low-cost, accessible adjunct to traditional depression therapies. However, until more robust clinical data emerge, the medical community urges a measured interpretation of current findings, prioritizing individualized care and evidence-based guidelines.